Group P7: Genetics
165 items with their schedule fees and Medicare benefits.
| Item | Fee | 75% | Out of hospital |
|---|---|---|---|
| 73287Cytogenetic analysis of whole chromosomes from non-blood tissue or fluid samples, including up to multiple tests per occasion. | $394.55 | $295.95 | $335.40 (85%) |
| 73289Cytogenetic study of all chromosomes from blood sample, including fluorescence in situ hybridisation if performed; one or more tests. | $358.95 | $269.25 | $305.15 (85%) |
| 73290Chromosome analysis of blood or bone marrow using cytogenetic techniques to diagnose and monitor blood cancers, including related studies if performed. | $394.55 | $295.95 | $335.40 (85%) |
| 73291Microarray analysis of blood or fresh tissue to detect chromosomal abnormalities in people with developmental delay, intellectual disability, autism, or multiple congenital abnormalities when standard cytogenetics are normal or not done, or in relati… | $230.95 | $173.25 | $196.35 (85%) |
| 73292Genome-wide microarray analysis to identify chromosomal abnormalities in patients with developmental delay, intellectual disability, autism, or multiple congenital abnormalities. | $589.90 | $442.45 | $501.45 (85%) |
| 73293Chromosome analysis of fetal tissue from miscarriage or termination products to identify genetic abnormalities and exclude maternal contamination. | $230.95 | $173.25 | $196.35 (85%) |
| 73294Genetic analysis of the PMP22 gene to diagnose peripheral neuropathy in an affected person or confirm a known familial mutation in a relative; includes up to multiple tests as needed. | $230.95 | $173.25 | $196.35 (85%) |
| 73295Germline BRCA1/BRCA2 testing for patients with advanced high-grade serous ovarian/fallopian tube/peritoneal cancer (when tumour tissue testing unavailable) or breast cancer, ordered by specialist to determine PBS treatment eligibility; once per lifet… | $1,200.00 | $900.00 | $1,095.50 (85%) |
| 73296Genetic testing for pathogenic variants in BRCA1, BRCA2 and other breast/ovarian cancer-related genes (including copy number variation) for patients with these cancers meeting >10% pre-test risk criteria; once per diagnosis on specialist request. | $1,200.00 | $900.00 | $1,095.50 (85%) |
| 73297Germline gene variant testing for breast, ovarian, fallopian tube or primary peritoneal cancer genes (including BRCA1/BRCA2) in patients with an affected biological relative, not previously tested under related items. | $400.00 | $300.00 | $340.00 (85%) |
| 73298Genetic testing for COL4A3, COL4A4, or COL4A5 variants in patients with clinical features and family history strongly suggestive of Alport syndrome, requested by a specialist or consultant physician. | $1,200.00 | $900.00 | $1,095.50 (85%) |
| 73299Genetic testing for COL4A3, COL4A4 or COL4A5 variants in first-degree relatives of patients with identified pathogenic mutations in these genes, when requested by a specialist or consultant physician and not previously tested under this item. | $400.00 | $300.00 | $340.00 (85%) |
| 73300FMR1 gene mutation testing for patients with intellectual disability, ataxia, neurodegeneration, or premature ovarian failure, or those with a relative carrying an FMR1 mutation; up to 1 test. | $101.30 | $76.00 | $86.15 (85%) |
| 73301BRCA testing of tumour tissue in advanced high-grade serous or epithelial ovarian, fallopian tube or primary peritoneal cancer to determine PARP inhibitor eligibility; once per diagnosis. | $1,200.00 | $900.00 | $1,095.50 (85%) |
| 73302Germline BRCA1/BRCA2 testing (including copy number variants) for patients with a pathogenic variant found on tumour testing, requested by a specialist; once per primary tumour diagnosis. | $400.00 | $300.00 | $340.00 (85%) |
| 73303Tumour tissue test for metastatic castration-resistant prostate cancer to determine BRCA status for PBS treatment eligibility, with germline testing if tumour results inconclusive; once per diagnosis, on specialist request. | $1,000.00 | $750.00 | $895.50 (85%) |
| 73304Germline BRCA1/BRCA2 testing in metastatic castration-resistant prostate cancer patients when tumour tissue testing is not feasible, ordered by a specialist to assess PBS treatment eligibility; once per lifetime. | $1,000.00 | $750.00 | $895.50 (85%) |
| 73305Southern Blot analysis to detect FMR1 gene mutations when initial testing (item 73300) results are inconclusive. | $202.65 | $152.00 | $172.30 (85%) |
| 73306EndoPredict gene expression profiling of ER-positive, HER2-negative breast cancer tissue to assess 10-year distant recurrence risk in patients with intermediate-risk disease suitable for adjuvant chemotherapy (node-negative or up to 3 positive nodes,… | $1,200.00 | $900.00 | $1,095.50 (85%) |
| 73307Testing tumour tissue from patients with advanced high-grade serous ovarian, fallopian tube or primary peritoneal cancer to determine homologous recombination deficiency and BRCA status for PARP inhibitor eligibility; once per primary diagnosis. | $3,000.00 | $2,250.00 | $2,895.50 (85%) |
| 73308Genetic testing for Factor V Leiden or other relevant mutations in patients with confirmed venous thrombosis or pulmonary embolism. | $36.45 | $27.35 | $31.00 (85%) |
| 73309Pathology test performed by an accredited pathology practitioner, subject to Rule 18 limitations on frequency or circumstances of claiming. | $36.45 | $27.35 | $31.00 (85%) |
| 73310MRD testing by next-generation sequencing on bone marrow or peripheral blood in acute lymphoblastic leukaemia patients to establish baseline or assess response to chemotherapy or salvage therapy, requested by a haematologist or oncologist. | $1,550.00 | $1,162.50 | $1,445.50 (85%) |
| 73311Genetic testing to identify abnormal genotypes in a first-degree relative of someone with proven abnormal genotype(s) identified under item 73308. | $36.45 | $27.35 | $31.00 (85%) |
| 73312Pathology test performed by an authorised pathology practitioner; may be one or more tests subject to Rule 18 frequency limits. | $36.45 | $27.35 | $31.00 (85%) |
| 73313Quantitative molecular assay for measurable residual disease in acute lymphoblastic leukaemia using bone marrow or peripheral blood, once per patient per episode or relapse, ordered by a haematologist or oncologist. | $3,000.00 | $2,250.00 | $2,895.50 (85%) |
| 73314Genetic testing to identify or characterise gene rearrangements and mutations in patients with acute myeloid, promyelocytic, or lymphoid leukaemia, or chronic myeloid leukaemia for diagnosis and monitoring purposes. | $230.95 | $173.25 | $196.35 (85%) |
| 73315Pathology test performed by an accredited pathology practitioner (APP), subject to referral rules and frequency limitations under MBS Rule 18. | $230.95 | $173.25 | $196.35 (85%) |
| 73316MRD testing by quantitative molecular assay on bone marrow or peripheral blood in acute lymphoblastic leukaemia patients post-chemotherapy or salvage therapy, requested by a haematologist or oncologist. | $780.00 | $585.00 | $675.50 (85%) |
| 73317Genetic testing for C282Y HFE mutation and other haemochromatosis mutations in patients with elevated iron markers, or those with first-degree relatives with haemochromatosis or relevant HFE mutations. | $36.45 | $27.35 | $31.00 (85%) |
| 73318Pathology test performed by a receiving allied health professional, subject to frequency and referral limitations under MBS rules 18 and 20. | $36.45 | $27.35 | $31.00 (85%) |
| 73319Testing for IDH1 variant status in cholangiocarcinoma tissue to determine eligibility for PBS-listed treatment, once per lifetime. | $340.00 | $255.00 | $289.00 (85%) |
| 73320HLA-B27 detection by nucleic acid amplification, unless provided as a pathologist-determinable service under item 73320. | $40.55 | $30.45 | $34.50 (85%) |
| 73321Pathology test performed by an Accredited Pathology Practitioner, subject to frequency and referral requirements under MBS rules 18 and 27. | $40.55 | $30.45 | $34.50 (85%) |
| 73322DPYD gene testing to detect variants affecting dihydropyrimidine dehydrogenase activity and predict fluoropyrimidine toxicity risk, requested by a specialist before, during or after fluoropyrimidine chemotherapy; once per lifetime. | $186.75 | $140.10 | $158.75 (85%) |
| 73323HLA-B5701 genetic testing to assess abacavir hypersensitivity risk before starting this antiretroviral medication, including specimen collection if required. | $40.55 | $30.45 | $34.50 (85%) |
| 73324Pathology test performed by an accredited pathology provider, subject to Rule 18 limitations on frequency and billing. | $40.95 | $30.75 | $34.85 (85%) |
| 73325JAK2 V617F variant allele frequency testing for suspected myeloproliferative neoplasm, performed by or on behalf of a specialist/consultant physician in patients with clinical and laboratory evidence. | $90.00 | $67.50 | $76.50 (85%) |
| 73326Gene rearrangement testing for FIP1L1-PDGFRA fusion in patients with mast cell disease, idiopathic hypereosinophilic syndrome, or chronic eosinophilic leukaemia to guide diagnosis and treatment decisions. | $230.95 | $173.25 | $196.35 (85%) |
| 73327Genetic testing for Thiopurine S-methyltransferase polymorphisms to identify patients at risk of toxicity from thiopurine drugs, including related services if performed. | $51.95 | $39.00 | $44.20 (85%) |
| 73329Nucleic acid multi-gene panel test of tumour tissue in cholangiocarcinoma patients to detect IDH1 variants and FGFR2 fusion status for determining PBS treatment eligibility; once per lifetime. | $800.00 | $600.00 | $695.50 (85%) |
| 73331Genetic testing of tumour tissue for RET gene variants in patients with confirmed medullary thyroid cancer to assess eligibility for PBS-listed treatments, requested by a specialist. | $400.00 | $300.00 | $340.00 (85%) |
| 73332In situ hybridization test on breast cancer tissue to determine HER2 gene amplification status for trastuzumab eligibility, requested by a specialist managing the patient's treatment. | $315.40 | $236.55 | $268.10 (85%) |
| 73333Germline VHL gene mutation testing for patients with clinical VHL syndrome features including hemangioblastomas, pheochromocytoma, renal cell carcinoma, or characteristic tumours/cysts of adrenal, kidney, pancreas, epididymis or broad ligament. | $600.00 | $450.00 | $510.00 (85%) |
| 73334Genetic testing for VHL gene mutations in blood relatives of patients with confirmed VHL mutations. | $340.00 | $255.00 | $289.00 (85%) |
| 73335Testing for somatic VHL gene mutations in patients with multiple tumours (at least 2 haemangioblastomas or one haemangioblastoma plus adrenal, kidney, pancreatic, or epididymal tumour) when germline VHL testing is negative. | $470.00 | $352.50 | $399.50 (85%) |
| 73336BRAF V600 mutation testing on tumour tissue from patients with stage III or IV metastatic cutaneous melanoma to determine eligibility for targeted therapy under PBS. | $230.95 | $173.25 | $196.35 (85%) |
| 73337EGFR testing on tumour tissue for newly diagnosed non-small cell lung cancer to determine eligibility for PBS-listed targeted treatments, requested by a specialist. | $397.35 | $298.05 | $337.75 (85%) |
| 73338RAS and BRAF gene testing on tumour tissue from metastatic colorectal cancer patients to determine eligibility for cetuximab, panitumumab, or encorafenib under PBS criteria. | $362.60 | $271.95 | $308.25 (85%) |
| 73339Genetic testing for RET gene mutations in patients with suspected MEN2, ordered by a specialist managing the patient's treatment; one test only. | $400.00 | $300.00 | $340.00 (85%) |
| 73340Genetic testing to detect a known RET gene mutation in an asymptomatic family member of a patient with a confirmed pathogenic RET mutation, ordered by the treating specialist; one test per eligible relative. | $200.00 | $150.00 | $170.00 (85%) |
| 73341FISH test on tumour tissue for ALK gene rearrangement status in newly diagnosed non-small cell lung cancer to determine PBS treatment eligibility, ordered by a specialist or consultant physician, excluding cases covered by items 73437 or 73439. | $400.00 | $300.00 | $340.00 (85%) |
| 73342In situ hybridisation test of stomach or gastro-oesophageal junction tumour tissue with HER2 IHC score 2+ or 3+ to confirm HER2 gene amplification for trastuzumab eligibility, requested by treating specialist. | $315.40 | $236.55 | $268.10 (85%) |
| 73343FISH or molecular testing for 17p deletion in chronic lymphocytic leukaemia or small lymphocytic lymphoma samples, ordered by a specialist at initial diagnosis, relapse, or progression when treatment change is planned. | $589.90 | $442.45 | $501.45 (85%) |
| 73344FISH test of lung cancer tissue to determine ROS1 gene arrangement status for treatment eligibility, requested by a specialist, excluding cases covered by items 73437 or 73439. | $400.00 | $300.00 | $340.00 (85%) |
| 73345Genetic testing for cystic fibrosis transmembrane conductance regulator variants in patients with clinical or laboratory findings suggesting cystic fibrosis or related disorder, when requested by a specialist managing the patient's treatment. | $500.00 | $375.00 | $425.00 (85%) |
| 73346Genetic testing of a pregnant patient and their partner for cystic fibrosis carrier status when fetal ultrasound shows echogenic gut, to determine if the fetus has cystic fibrosis or a related disorder. | $500.00 | $375.00 | $425.00 (85%) |
| 73347Genetic testing of a prospective parent for cystic fibrosis variants to assess fetal risk when the fetus shows echogenic gut on ultrasound, requested by a specialist managing the patient. | $500.00 | $375.00 | $425.00 (85%) |
| 73348Genetic testing for asymptomatic cystic fibrosis carrier status in patients with confirmed family history of pathogenic CFTR variants and at least 6% personal risk of being a heterozygous carrier. | $250.00 | $187.50 | $212.50 (85%) |
| 73349Genetic testing for cystic fibrosis carrier status in a patient whose reproductive partner is already confirmed to carry pathogenic CFTR variants, requested by the treating specialist to assess reproductive risk. | $500.00 | $375.00 | $425.00 (85%) |
| 73350Non-invasive prenatal testing for cystic fibrosis in pregnant patients where both parents carry known CF gene mutations and fetus has ≥25% risk, ordered by specialist managing patient care. | $250.00 | $187.50 | $212.50 (85%) |
| 73351Testing tumour tissue for EGFR T790M mutation in patients with advanced/metastatic NSCLC who have progressed after EGFR TKI treatment, to determine eligibility for osimertinib PBS funding. | $397.35 | $298.05 | $337.75 (85%) |
| 73352Genetic testing for familial hypercholesterolaemia mutations (LDLR, PCSK9, APOB genes) for undiagnosed patients with high LDL-cholesterol or clinical indicators of familial disease; once per lifetime. | $1,200.00 | $900.00 | $1,095.50 (85%) |
| 73353Genetic testing to identify a familial hypercholesterolaemia mutation in a patient with an affected first or second-degree relative; once per lifetime. | $400.00 | $300.00 | $340.00 (85%) |
| 73354Genetic testing for mismatch repair gene variants (MLH1, MSH2, MSH6, PMS2, EPCAM) in patients with suspected Lynch syndrome based on immunohistochemistry loss or endometrial cancer with >10% Lynch syndrome risk, on specialist request. | $1,200.00 | $900.00 | $1,095.50 (85%) |
| 73355Genetic testing for APC and MUTYH gene variants including copy number variation in patients with adenomatous polyposis and >10% clinical or family history risk of familial adenomatous polyposis or MUTYH-associated polyposis, ordered by a specialist o… | $1,200.00 | $900.00 | $1,095.50 (85%) |
| 73356Genetic testing for SMAD4, BMPR1A, STK11 and GREM1 variants in patients with non-adenomatous polyposis and >10% risk of juvenile polyposis, Peutz-Jeghers or hereditary mixed polyposis syndrome, requested by a specialist. | $1,200.00 | $900.00 | $1,095.50 (85%) |
| 73357Genetic testing for pathogenic variants (including copy number changes) in specified genes for patients with a family history of mutations, requested by a specialist, when no previous genetic testing for these genes has been done. | $400.00 | $300.00 | $340.00 (85%) |
| 73358Whole exome or genome sequencing for germline variants causing monogenic disorders in children aged 10 years or under with suspected monogenic conditions (dysmorphic features with congenital anomalies or moderate intellectual disability/developmental… | $2,100.00 | $1,575.00 | $1,995.50 (85%) |
| 73359Whole exome or genome sequencing to identify germline variants causing monogenic disorders in children aged 10 or under with dysmorphic features, structural anomalies, or moderate intellectual disability, ordered by clinical geneticist or paediatrici… | $2,900.00 | $2,175.00 | $2,795.50 (85%) |
| 73360Re-analysis of whole exome or genome data to identify previously unreported germline variants in patients aged ≤15 years suspected of monogenic conditions, requested by a clinical geneticist or paediatrician after consultation with genetics, performe… | $500.00 | $375.00 | $425.00 (85%) |
| 73361Single gene variant testing for a person with an affected sibling who has had the causative variant identified, requested by a clinical geneticist or specialist paediatrician after genetics consultation; applicable once per variant per lifetime. | $400.00 | $300.00 | $340.00 (85%) |
| 73362Genetic testing for a single gene variant in someone with a first-degree relative who has a known monogenic condition, to help with reproductive decisions; performed once per variant per lifetime. | $400.00 | $300.00 | $340.00 (85%) |
| 73363Single gene variant testing in a biological relative of a patient with a known monogenic condition to confirm segregation of a potentially causative variant identified in the patient, requested by a clinical geneticist or paediatrician; once per vari… | $400.00 | $300.00 | $340.00 (85%) |
| 73364Analysis of tumour tissue for MYC gene rearrangement characterisation, with BCL2/BCL6 testing if MYC positive, for patients with MYC-positive immunohistochemistry and diffuse large B-cell or high-grade B-cell lymphoma; once per lifetime. | $400.00 | $300.00 | $340.00 (85%) |
| 73365Specialist-requested analysis of tumour tissue to identify MYC gene rearrangement in patients with clinical or laboratory evidence of Burkitt lymphoma, limited to once per lifetime. | $340.00 | $255.00 | $289.00 (85%) |
| 73366Specialist-ordered tumour tissue analysis for CCND1 and/or CCND2 gene rearrangement to confirm mantle cell lymphoma diagnosis; once per lifetime. | $400.00 | $300.00 | $340.00 (85%) |
| 73367Genetic analysis of tumour tissue for isochromosome 7q in patients with suspected hepatosplenic T-cell lymphoma, requested by a specialist; one-time only. | $340.00 | $255.00 | $289.00 (85%) |
| 73368Specialist-requested analysis of tumour tissue to identify DUSP22 or TP63 gene rearrangements in patients with ALK negative anaplastic large cell lymphoma; once per lifetime only. | $400.00 | $300.00 | $340.00 (85%) |
| 73369Blood or bone marrow test for TCL1A or MTCP1 gene rearrangements in patients with T-cell prolymphocytic leukaemia, requested by a specialist; once per lifetime. | $400.00 | $300.00 | $340.00 (85%) |
| 73370Genetic testing of blood or bone marrow for specific chromosome abnormalities in newly diagnosed plasma cell myeloma patients, one-time only. | $500.00 | $375.00 | $425.00 (85%) |
| 73371Molecular analysis of brain tumour tissue for 1p/19q co-deletion status in patients with suspected oligodendroglial glioma, requested by a specialist, performed once per lifetime. | $340.00 | $255.00 | $289.00 (85%) |
| 73372Molecular analysis of tumour tissue to identify IDH1/2 variants in patients with glial neoplasm and negative IDH1 immunohistochemistry, requested by specialist; once per lifetime. | $340.00 | $255.00 | $289.00 (85%) |
| 73373MGMT promoter methylation analysis of tumour tissue in glioblastoma patients, requested by a specialist; one lifetime only. | $400.00 | $300.00 | $340.00 (85%) |
| 73374Molecular analysis of tumour tissue for one gene to detect copy number changes, gene rearrangements, or other molecular changes associated with sarcoma, requested by a specialist for a patient with clinical or laboratory evidence of sarcoma; applicab… | $340.00 | $255.00 | $289.00 (85%) |
| 73375Genetic analysis of 2 or 3 genes for tumour diagnosis, limited to once per diagnostic episode. | $400.00 | $300.00 | $340.00 (85%) |
| 73376Genetic analysis of 4 or more genes for tumour diagnosis, limited to once per tumour diagnostic episode. | $800.00 | $600.00 | $695.50 (85%) |
| 73377Testing of ovarian tumour tissue for FOXL2.402C>G mutation status in patients with suspected granulosa cell tumour, performed once per lifetime. | $250.00 | $187.50 | $212.50 (85%) |
| 73378Genetic testing of tumour tissue to determine NUTM1 gene status in patients with suspected midline NUT carcinoma, performed once per lifetime. | $340.00 | $255.00 | $289.00 (85%) |
| 73379Molecular analysis of breast tissue to detect ETV6-NTRK3 gene rearrangement in patients with suspected secretory carcinoma, available once per lifetime. | $340.00 | $255.00 | $289.00 (85%) |
| 73380Genetic testing of tumour tissue to identify MAML2 gene rearrangement in patients with mucoepidermoid carcinoma, performed once per lifetime on specialist request. | $340.00 | $255.00 | $289.00 (85%) |
| 73381Pathology testing for ETV6-NTRK3 gene rearrangement in salivary gland tumour tissue to confirm mammary analogue secretory carcinoma diagnosis; requested by specialist; once per lifetime. | $340.00 | $255.00 | $289.00 (85%) |
| 73382Genetic testing of salivary gland tumour tissue for EWSR1 gene rearrangement to confirm hyalinising clear cell carcinoma diagnosis, once per lifetime. | $340.00 | $255.00 | $289.00 (85%) |
| 73383Genetic analysis of tumour tissue for TFE3 or TFEB gene rearrangement in renal cell carcinoma patients, ordered by a specialist; covered once per lifetime. | $400.00 | $300.00 | $340.00 (85%) |
| 73384Genetic analysis of patient and partner samples for pre-implantation testing, requested by a specialist, limited to once per disorder per reproductive relationship. | $1,736.00 | $1,302.00 | $1,631.50 (85%) |
| 73385Genetic analysis of embryonic tissue from one embryo for pre-implantation testing, requested by a specialist, performed once per embryo per assisted reproductive treatment cycle. | $635.00 | $476.25 | $539.75 (85%) |
| 73386Genetic analysis of embryonic tissue from up to 2 embryos for pre-implantation testing in a single assisted reproductive cycle, requested by a specialist; limited to once per cycle and not applicable if items 73385 or 73387 already apply. | $1,270.00 | $952.50 | $1,165.50 (85%) |
| 73387Genetic analysis of embryonic tissue from 3+ embryos in a single IVF cycle for pre-implantation genetic testing, requested by a specialist, once per cycle. | $1,905.00 | $1,428.75 | $1,800.50 (85%) |
| 73388Chromosomal analysis of fetal samples (amniocentesis or chorionic villus sampling) via genome-wide microarray to detect constitutional genetic abnormalities when major fetal structural abnormalities are present on ultrasound or nuchal translucency ex… | $589.90 | $442.45 | $501.45 (85%) |
| 73389Genetic analysis of pregnancy tissue to determine ploidy status in suspected molar pregnancy, covered once per pregnancy. | $340.00 | $255.00 | $289.00 (85%) |
| 73391Genome-wide microarray analysis of chromosomes for diagnostic evaluation in a patient with multiple myeloma, covered once per lifetime. | $589.90 | $442.45 | $501.45 (85%) |
| 73392Genetic testing for pathogenic variants in 22 cardiomyopathy-related genes (including MYBPC3, MYH7, LMNA, SCN5A) for patients with clinical, family or laboratory evidence of hypertrophic, dilated or arrhythmogenic cardiomyopathy; specialist-requested… | $1,200.00 | $900.00 | $1,095.50 (85%) |
| 73393Genetic testing for cardiomyopathy-related variants in first- or second-degree relatives of affected patients, ordered by specialist, once per variant per lifetime. | $400.00 | $300.00 | $340.00 (85%) |
| 73394Genetic testing for recessive cardiomyopathy genes in reproductive partners of known carriers with low probability of being affected, once per gene per lifetime. | $1,200.00 | $900.00 | $1,095.50 (85%) |
| 73395Re-analysis of whole exome or genome data to identify new germline variants in suspected heritable cardiomyopathy, requested by a clinical geneticist or cardiologist, at least 18 months after initial sequencing, limited to twice per lifetime. | $500.00 | $375.00 | $425.00 (85%) |
| 73396Genetic testing for JAK2 exon 12 mutations in patients with suspected polycythaemia vera, when requested by a specialist or consultant physician. | $90.00 | $67.50 | $76.50 (85%) |
| 73397Genetic testing for CALR and MPL gene variants in patients with suspected essential thrombocythaemia or primary myelofibrosis, when requested by a specialist or consultant physician. | $200.00 | $150.00 | $170.00 (85%) |
| 73398Genetic testing for myeloproliferative neoplasms analyzing JAK2, CALR, MPL and at least 5 other genes to confirm polycythaemia vera or essential thrombocythaemia diagnosis; one test per diagnostic episode, specialist-requested only. | $420.00 | $315.00 | $357.00 (85%) |
| 73399Genetic testing of at least 20 genes (including JAK2, CALR, and MPL) to diagnose primary myelofibrosis in stem cell transplant-eligible patients; once per diagnostic episode, on specialist request. | $700.00 | $525.00 | $595.50 (85%) |
| 73400Genetic testing for HLA variants (carbamazepine/oxcarbazepine risk prediction) before or during treatment initiation to assess severe drug hypersensitivity risk; once per lifetime. | $139.00 | $104.25 | $118.15 (85%) |
| 73401Whole exome or genome sequencing to identify germline gene variants in heritable cystic kidney disease, requested by a clinical geneticist or specialist nephrologist for patients with renal abnormality suspected of monogenic condition; once per lifet… | $2,100.00 | $1,575.00 | $1,995.50 (85%) |
| 73402Whole exome or genome sequencing to identify germline gene variants in heritable kidney disease, requested by a clinical geneticist or nephrologist for patients with chronic kidney disease suspected of having a monogenic condition; once per lifetime. | $2,100.00 | $1,575.00 | $1,995.50 (85%) |
| 73403Re-analysis of existing genetic data to characterise previously unreported germline variants in patients with suspected monogenic conditions, requested by a clinical geneticist or specialist paediatrician, limited to once per 18 months and twice life… | $500.00 | $375.00 | $425.00 (85%) |
| 73404Single gene variant detection in a patient with a first-degree relative with known monogenic kidney disease, requested by a clinical geneticist or specialist providing genetic counselling, after the relative's causative variant has been identified th… | $400.00 | $300.00 | $340.00 (85%) |
| 73405Single gene variant testing for heritable kidney disease in reproductive partners of known carriers, requested by a clinical geneticist or specialist nephrologist, where the causative gene has been identified and the test detects at least 95% of path… | $1,200.00 | $900.00 | $1,095.50 (85%) |
| 73406Prenatal genetic testing for monogenic kidney disease variants in fetuses when a parent or partner carries a known pathogenic variant causing heritable kidney disease, requested by a clinical geneticist or nephrologist. | $400.00 | $300.00 | $340.00 (85%) |
| 73410Genetic testing for alpha thalassaemia (HBA1/HBA2 gene deletions) in reproductive-aged patients with abnormal red cell indices and positive screening, reproductive partners of affected persons, or partners of carriers with heterozygous deletions. | $100.00 | $75.00 | $85.00 (85%) |
| 73411Sequencing of HBA1 or HBA2 genes to identify rare alpha-thalassaemia variants when deletion testing is inconclusive, for reproductive-age patients or carrier status determination in partners; once per gene per lifetime. | $400.00 | $300.00 | $340.00 (85%) |
| 73412Deletion testing of HBA1 and HBA2 genes to confirm suspected large deletion variants in patients of reproductive age with alpha thalassaemia or their reproductive partners, when initial deletion testing was inconclusive. | $250.00 | $187.50 | $212.50 (85%) |
| 73413Non-deletion testing of HBA1 and HBA2 genes using non-sequencing techniques when deletion testing is inconclusive, for diagnosing alpha thalassaemia in reproductive-age patients or determining carrier status in reproductive partners. | $250.00 | $187.50 | $212.50 (85%) |
| 73416Genetic testing for variants in cardiac arrhythmia-related genes (including KCNQ1, KCNH2, SCN5A and 17 others) for patients with clinical or family history suggesting inherited channelopathy with >10% pathogenic variant risk; once per lifetime. | $1,200.00 | $900.00 | $1,095.50 (85%) |
| 73417Genetic testing to identify inherited heart rhythm disorder variants in relatives of affected family members, performed once per variant per lifetime. | $400.00 | $300.00 | $340.00 (85%) |
| 73418Genetic testing of one or more recessive genes in reproductive partners of known cardiac arrhythmia/channelopathy carriers to assess reproductive risk, when carrier status is unknown and clinical findings suggest low disease probability; once per gen… | $1,200.00 | $900.00 | $1,095.50 (85%) |
| 73419Re-analysis of existing whole exome or genome data to characterise new germline variants in patients with suspected inherited cardiac arrhythmias or channelopathies, requested by a clinical geneticist or cardiologist, performed at least 18 months aft… | $500.00 | $375.00 | $425.00 (85%) |
| 73420Non-invasive blood test for RhD-negative pregnant patients to detect fetal RHD gene in maternal circulation, excluding those previously alloimmunised against RhD. | $150.40 | $112.80 | $127.85 (85%) |
| 73421Non-invasive prenatal testing of maternal blood to detect fetal RHD gene in RhD negative pregnant patients who have been previously alloimmunised against RhD. | $550.00 | $412.50 | $467.50 (85%) |
| 73422Gene panel testing to identify genetic variants causing neuromuscular disorders in patients with clinical signs and symptoms, requested by a specialist after excluding non-genetic causes; once per lifetime. | $1,200.00 | $900.00 | $1,095.50 (85%) |
| 73423Genetic testing to detect a known gene variant in a family member of someone with an identified neuromuscular disorder mutation, requested by a specialist; once per variant. | $500.00 | $375.00 | $425.00 (85%) |
| 73424Prenatal testing for known pathogenic familial genetic variants in neuromuscular disorders, ordered by a specialist, when the same variant was previously identified in a family member via diagnostic genetic testing; covers once per pregnancy. | $1,600.00 | $1,200.00 | $1,495.50 (85%) |
| 73425Prenatal testing via gene panel for suspected fetal genetic neuromuscular disorder, ordered by specialist after non-genetic causes excluded, using fetal sample; once per pregnancy. | $1,800.00 | $1,350.00 | $1,695.50 (85%) |
| 73426Prenatal gene panel testing for suspected fetal neuromuscular disorders via specialist request, using fetal and parental samples to identify unknown variants and assess maternal contamination; once per pregnancy. | $2,400.00 | $1,800.00 | $2,295.50 (85%) |
| 73427Genetic testing of a single gene to characterise a germline variant in a patient whose partner carries a documented pathogenic recessive variant for neuromuscular disorder, requested by a specialist; limited to once per gene. | $1,200.00 | $900.00 | $1,095.50 (85%) |
| 73428Re-analysis of whole genome or exome data to characterise previously unreported gene variants related to the patient's clinical phenotype, requested by a clinical geneticist or specialist paediatrician after consultation with a clinical geneticist; l… | $500.00 | $375.00 | $425.00 (85%) |
| 73429Genetic panel testing for glioma, glioneuronal tumour or glioblastoma patients to assess IDH1/2, 1p/19q, H3F3A, TERT, EGFR, CDKN2A/B and BRAF variants for diagnosis and classification; one test per diagnostic episode when requested by a specialist. | $887.90 | $665.95 | $783.40 (85%) |
| 73430FISH testing of tumour tissue to detect NTRK gene fusion in children under 18, mammary analogue secretory carcinoma of salivary gland, or secretory breast carcinoma, when requested by a specialist to determine eligibility for Trk inhibitor therapy; o… | $400.00 | $300.00 | $340.00 (85%) |
| 73431I don't have access to the specific MBS item 73430 descriptor. To provide an accurate summary, I would need you to share the item descriptor text. Please provide the full descriptor for item 73430, and I'll create a concise plain-English summary of… | $533.00 | $399.75 | $453.05 (85%) |
| 73432Three or more pathology tests from the specified list, ordered together by a doctor for diagnostic purposes. | $667.00 | $500.25 | $566.95 (85%) |
| 73433NGS testing for NTRK fusions in tumour tissue from patients with locally advanced/metastatic solid tumours (children under 18, mammary analogue secretory carcinoma, or secretory breast carcinoma) to determine eligibility for Trk inhibitor therapy; on… | $1,000.00 | $750.00 | $895.50 (85%) |
| 73434Specialist-requested genetic testing to detect pathogenic variants in neuromuscular disorder patients, their relatives, or reproductive partners of carriers; once per gene per lifetime. | $392.00 | $294.00 | $333.20 (85%) |
| 73435Testing for DUX4 gene variants in patients with suspected neuromuscular disorder or their relatives with confirmed pathogenic variants, ordered by a specialist; once per gene per lifetime. | $1,000.00 | $750.00 | $895.50 (85%) |
| 73436Testing lung cancer tumour tissue for MET exon 14 skipping alterations to determine eligibility for PBS-funded treatment, requested by a specialist. | $397.35 | $298.05 | $337.75 (85%) |
| 73437Multi-gene panel testing of lung cancer tumour tissue to detect EGFR, BRAF, KRAS, MET variants and ALK, ROS1, RET, NTRK fusion status for treatment eligibility, requested by a specialist. | $1,247.00 | $935.25 | $1,142.50 (85%) |
| 73438Multi-gene panel test on tumour tissue from newly diagnosed non-small cell lung cancer patients to detect variants in EGFR, BRAF, KRAS and MET exon 14 for determining PBS treatment eligibility, requested by a specialist or consultant physician. | $682.35 | $511.80 | $580.00 (85%) |
| 73439Multi-gene panel testing of tumour tissue in newly diagnosed non-small cell lung cancer without EGFR, KRAS, BRAF or MET exon14 activating variants to assess fusion status (ALK, ROS1, RET, NTRK1/2/3) for treatment eligibility, requested by a specialis… | $682.35 | $511.80 | $580.00 (85%) |
| 73440Genomic testing for genes causing childhood hearing loss (moderate-severe-profound sensorineural, auditory neuropathy or mixed, onset before age 18), requested by specialist, once per lifetime. | $1,200.00 | $900.00 | $1,095.50 (85%) |
| 73441Genomic testing with copy number variant analysis for genes causing childhood hearing loss (moderate-profound, sensorineural/auditory neuropathy/mixed onset before age 18), requested by specialist, including patient and both parents' samples, once pe… | $2,100.00 | $1,575.00 | $1,995.50 (85%) |
| 73442Re-analysis of whole exome or genome data for previously unreported germline variants causing childhood hearing loss, requested by a specialist, performed at least 24 months after initial testing; twice per lifetime. | $500.00 | $375.00 | $425.00 (85%) |
| 73443Genetic testing to characterise known familial germline variants causing childhood hearing loss in relatives of an affected proband, when proband test results are available to the laboratory. | $400.00 | $300.00 | $340.00 (85%) |
| 73444Genetic testing of a reproductive partner to identify carrier status for recessive hearing loss genes, when requested by a specialist for a partner of an affected patient with confirmed pathogenic variants. | $1,200.00 | $900.00 | $1,095.50 (85%) |
| 73445Genetic testing of 25+ genes using DNA and RNA for diagnosis, prognosis or management of suspected myeloid haematological malignancy, ordered by a specialist; covered once per diagnostic episode at initial diagnosis, progression or relapse. | $1,100.00 | $825.00 | $995.50 (85%) |
| 73446Genetic testing of at least 25 genes using DNA and RNA for patients with suspected lymphoid haematological malignancy to establish diagnosis, prognosis or management, requested by a specialist; once per diagnostic episode at diagnosis, progression or… | $1,100.00 | $825.00 | $995.50 (85%) |
| 73447Genetic testing of at least 25 genes in DNA to characterise variants in suspected myeloid haematological malignancies for diagnosis, prognosis and management; applicable once per diagnostic episode at diagnosis, progression or relapse. | $927.90 | $695.95 | $823.40 (85%) |
| 73448DNA panel testing of at least 25 genes to characterize variants in suspected lymphoid haematological malignancy for diagnosis, prognosis, or management; requested by a specialist; once per diagnostic episode, at diagnosis, progression, or relapse. | $927.90 | $695.95 | $823.40 (85%) |
| 73451Carrier screening for pregnant or planning-to-become-pregnant patients for cystic fibrosis, spinal muscular atrophy, or fragile X syndrome; once per lifetime. | $400.00 | $300.00 | $340.00 (85%) |
| 73452Carrier testing of reproductive partner for CFTR or SMN1 pathogenic variants to determine reproductive risk of cystic fibrosis or spinal muscular atrophy; one test per condition per lifetime. | $400.00 | $300.00 | $340.00 (85%) |
| 73453Genetic testing to determine carrier status for 12 recessive disorders in reproductive-age patients of Ashkenazi Jewish descent, including cystic fibrosis, Tay-Sachs, and spinal muscular atrophy; once per lifetime. | $425.00 | $318.75 | $361.25 (85%) |
| 73454Whole gene sequencing for a reproductive partner of someone with a genetic carrier status or condition (excluding cystic fibrosis, fragile-X, or SMA) to assess couple's reproductive risk; once per couple per lifetime. | $1,200.00 | $900.00 | $1,095.50 (85%) |
| 73455Non-invasive prenatal testing for fetal genetic conditions when a parent carries or has a genetic condition with at least 25% inheritance risk, requested by a specialist. | $1,600.00 | $1,200.00 | $1,495.50 (85%) |
| 73456Genomic sequencing (whole genome, whole exome, or mitochondrial DNA) to diagnose suspected mitochondrial disease in patients with clinical features like organ dysfunction, seizures, cardiomyopathy, hearing/vision loss, or family history; requires spe… | $2,100.00 | $1,575.00 | $1,995.50 (85%) |
| 73457Whole genome or exome/mitochondrial DNA sequencing for patients with suspected mitochondrial disease, including parents' samples, requested by specialist with clinical indicators present, not previously funded under related items. | $3,300.00 | $2,475.00 | $3,195.50 (85%) |
| 73458Re-analysis of genomic data (whole genome, exome, or mitochondrial DNA) to identify previously unreported germline variants in suspected monogenic mitochondrial disease, requested by a specialist, performed at least 24 months after initial testing; l… | $500.00 | $375.00 | $425.00 (85%) |
| 73459Prenatal genetic testing to detect in a fetus gene variants present in parents or siblings, ordered by a specialist, when the variant has been confirmed by lab findings in a first-degree relative. | $1,600.00 | $1,200.00 | $1,495.50 (85%) |
| 73460DNA sequencing to identify mitochondrial DNA deletions or variants in patients with suspected mitochondrial disease, requested by specialist, when clinical features are present and prior testing was non-informative; limited to 3 times lifetime. | $450.00 | $337.50 | $382.50 (85%) |
| 73461Whole gene testing to identify all germline variants in a person whose reproductive partner carries a confirmed pathogenic recessive mitochondrial disease variant, upon specialist request. | $1,200.00 | $900.00 | $1,095.50 (85%) |
| 73462Genetic testing for a single mitochondrial disease variant in a person with an affected biological relative, requested by a specialist or consultant physician. | $400.00 | $300.00 | $340.00 (85%) |